

## HIGHLIGHTS

- 13 new countries/territories/areas have reported cases of COVID-19 in the past 24 hours.
- The Director-General said yesterday that Europe has now become the epicenter of the pandemic, with more reported cases and deaths than the rest of the world combined, apart from China. Many countries are now acting on the eight pillars of WHO’s Strategic Preparedness and Response Plan. For more details, please see [here](#).
- WHO published guidance on ‘Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected’ on 13 March. The document provides clinicians with updated interim guidance on timely, effective, and safe supportive management of patients with suspected and confirmed COVID-19. For more details, please see [here](#).

## SITUATION IN NUMBERS total and new cases in last 24 hours

### Globally

142 539 confirmed (9769 new)  
5393 deaths (438 new)

### China

81 021 confirmed (18 new)  
3194 deaths (14 new)


### Outside of China

61 518 confirmed (9751 new)  
2199 deaths (424 new)  
135 countries/territories/  
areas (13 new)

## WHO RISK ASSESSMENT

China	Very High
Regional Level	Very High
Global Level	Very High

Figure 1. Countries, territories or areas with reported confirmed cases of COVID-19, 14 March 2020



## SURVEILLANCE

**Table 1. Confirmed and suspected cases of COVID-19 acute respiratory disease reported by provinces, regions and cities in China, Data as of 14 March 2020**

Province/ Region/ City	Population (10,000s)	In last 24 hours			Cumulative	
		Confirmed cases	Suspected cases	Deaths	Confirmed cases	Deaths
Hubei	5917	4	0	13	67790	3075
Guangdong	11346	0	0	0	1356	8
Henan	9605	0	0	0	1273	22
Zhejiang	5737	0	0	0	1227	1
Hunan	6899	0	0	0	1018	4
Anhui	6324	0	0	0	990	6
Jiangxi	4648	0	0	0	935	1
Shandong	10047	0	0	0	760	7
Jiangsu	8051	0	0	0	631	0
Chongqing	3102	0	0	0	576	6
Sichuan	8341	0	0	0	539	3
Heilongjiang	3773	0	0	0	482	13
Beijing	2154	1	5	0	437	8
Shanghai	2424	4	11	0	350	3
Hebei	7556	0	0	0	318	6
Fujian	3941	0	0	0	296	1
Guangxi	4926	0	0	0	252	2
Shaanxi	3864	0	0	0	245	2
Yunnan	4830	0	0	0	174	2
Hainan	934	0	0	0	168	6
Guizhou	3600	0	0	0	146	2
Hong Kong SAR	745	6	0	1	137	4
Tianjin	1560	0	1	0	136	3
Shanxi	3718	0	0	0	133	0
Gansu	2637	2	0	0	129	2
Liaoning	4359	0	0	0	125	1
Jilin	2704	0	0	0	93	1
Xinjiang	2487	0	0	0	76	3
Ningxia	688	0	0	0	75	0
Inner Mongolia	2534	0	0	0	75	1
Taipei and environs	2359	1	0	0	50	1
Qinghai	603	0	0	0	18	0
Macao SAR	66	0	0	0	10	0
Xizang	344	0	0	0	1	0
<b>Total</b>	<b>142823</b>	<b>18</b>	<b>17</b>	<b>14</b>	<b>81021</b>	<b>3194</b>

**Table 2. Countries, territories or areas outside China with reported laboratory-confirmed COVID-19 cases and deaths. Data as of 14 March 2020\***

Reporting Country/ Territory/Area <sup>†</sup>	Total confirmed ‡ cases	Total confirmed new cases	Total deaths	Total new deaths	Transmission classification <sup>§</sup>	Days since last reported case
<b>Western Pacific Region</b>						
Republic of Korea	8086	107	72	6	Local transmission	0
Japan	716	41	21	2	Local transmission	0
Singapore	200	13	0	0	Local transmission	0
Australia	197	57	3	0	Local transmission	0
Malaysia	197	68	0	0	Local transmission	0
Philippines	64	12	2	0	Local transmission	0
Viet Nam	48	9	0	0	Local transmission	0
Brunei Darussalam	25	13	0	0	Local transmission	0
Cambodia	7	2	0	0	Local transmission	0
New Zealand	6	1	0	0	Local transmission	0
Mongolia	1	0	0	0	Imported cases only	4
<b>Territories**</b>						
French Polynesia	1	0	0	0	Imported cases only	2
<b>European Region</b>						
Italy	17660	2547	1268	252	Local transmission	0
Spain	4231	1266	120	36	Local transmission	0
France	3640	780	79	18	Local transmission	0
Germany	3062	693	6	0	Local transmission	0
Switzerland	1125	267	6	0	Local transmission	0
Netherlands	804	190	10	5	Local transmission	0
The United Kingdom	802	208	10	2	Local transmission	0
Denmark	801	127	0	0	Local transmission	0
Sweden	775	155	0	0	Local transmission	0
Norway	750	261	1	1	Local transmission	0
Belgium	599	285	0	0	Local transmission	0
Austria	504	143	1	0	Local transmission	0
Czechia	150	34	0	0	Local transmission	0
Slovenia	141	84	0	0	Local transmission	0
Portugal	112	71	0	0	Local transmission	0
Finland	109	0	0	0	Local transmission	1
Israel	100	25	0	0	Local transmission	0
Greece	98	0	1	0	Local transmission	2
Ireland	90	20	1	0	Local transmission	0
Estonia	79	66	0	0	Local transmission	0
San Marino	66	3	2	0	Local transmission	0
Romania	64	16	0	0	Local transmission	0
Poland	64	15	1	0	Local transmission	0
Iceland	61	0	0	0	Local transmission	4
Luxembourg	38	21	1	1	Local transmission	0
Russian Federation	34	0	0	0	Imported cases only	1
Albania	33	10	1	1	Local transmission	0
Serbia	31	12	0	0	Local transmission	0
Slovakia	30	9	0	0	Local transmission	0
Croatia	27	11	0	0	Local transmission	0
Georgia	25	0	0	0	Imported cases only	1
Belarus	21	9	0	0	Local transmission	0
Hungary	19	3	0	0	Local transmission	0
Latvia	16	0	0	0	Imported cases only	2

Cyprus	14	8	0	0	Imported cases only	0
Malta	12	3	0	0	Imported cases only	0
Azerbaijan	11	0	0	0	Imported cases only	1
Bosnia and Herzegovina	11	7	0	0	Local transmission	0
North Macedonia	9	2	0	0	Local transmission	0
Armenia	8	7	0	0	Imported cases only	0
Republic of Moldova	8	4	0	0	Imported cases only	0
Bulgaria	7	0	1	0	Local transmission	2
Lithuania	6	3	0	0	Imported cases only	0
Turkey	5	4	0	0	Imported cases only	0
Liechtenstein	4	0	0	0	Imported cases only	1
Ukraine	3	0	1	1	Local transmission	0
Andorra	2	1	0	0	Imported cases only	0
Monaco	2	1	0	0	Under investigation	0
Holy See	1	0	0	0	Under investigation	8
<b>Territories**</b>						
Faroe Islands	3	1	0	0	Imported cases only	0
Gibraltar	1	0	0	0	Under investigation	10
Guernsey	1	0	0	0	Imported cases only	4
Jersey	2	0	0	0	Imported cases only	1
<b>South-East Asia Region</b>						
India	82	8	2	1	Local transmission	0
Thailand	75	0	1	0	Local transmission	1
Indonesia	69	35	3	2	Local transmission	0
Maldives	9	1	0	0	Local transmission	0
Sri Lanka	6	3	0	0	Local transmission	0
Bangladesh	3	0	0	0	Local transmission	5
Bhutan	1	0	0	0	Imported cases only	8
Nepal	1	0	0	0	Imported cases only	50
<b>Eastern Mediterranean Region</b>						
Iran (Islamic Republic of)	11364	1289	514	85	Local transmission	0
Qatar	262	0	0	0	Local transmission	2
Bahrain	210	15	0	0	Local transmission	0
Kuwait	100	20	0	0	Local transmission	0
Egypt	93	26	2	1	Local transmission	0
Iraq	93	23	9	2	Local transmission	0
United Arab Emirates	85	0	0	0	Local transmission	1
Lebanon	77	11	4	1	Local transmission	0
Saudi Arabia	62	41	0	0	Local transmission	0
Pakistan	21	1	0	0	Imported cases only	0
Oman	19	1	0	0	Imported cases only	0
Tunisia	16	9	0	0	Local transmission	0
Afghanistan	7	0	0	0	Imported cases only	2
Morocco	7	1	1	0	Local transmission	0
Jordan	1	0	0	0	Imported cases only	11
Sudan	1	1	0	0	Imported cases only	0
<b>Territories**</b>						
occupied Palestinian territory	35	4	0	0	Local transmission	0
<b>Region of the Americas</b>						
United States of America	1678	414	41	5	Local transmission	0

Canada	176	38	1	0	Local transmission	0
Brazil	98	21	0	0	Local transmission	0
Chile	43	10	0	0	Local transmission	0
Argentina	34	3	2	1	Local transmission	0
Peru	28	6	0	0	Local transmission	0
Panama	27	13	1	0	Local transmission	0
Mexico	26	14	0	0	Imported cases only	0
Costa Rica	23	1	0	0	Local transmission	0
Ecuador	23	6	0	0	Local transmission	0
Colombia	16	7	0	0	Imported cases only	0
Jamaica	7	6	0	0	Imported cases only	0
Guyana	6	5	1	0	Imported cases only	0
Paraguay	6	1	0	0	Local transmission	0
Dominican Republic	5	0	0	0	Imported cases only	4
Cuba	4	1	0	0	Imported cases only	0
Bolivia (Plurinational State of)	3	0	0	0	Imported cases only	1
Puerto Rico	3	3	0	0	Imported cases only	0
Honduras	2	0	0	0	Imported cases only	2
Venezuela (Bolivarian Republic of)	2	2	0	0	Imported cases only	0
Antigua and Barbuda	1	1	0	0	Imported cases only	0
Guadeloupe	1	1	0	0	Imported cases only	0
Saint Vincent and the Grenadines	1	0	0	0	Imported cases only	1
Trinidad and Tobago	1	1	0	0	Imported cases only	0
<b>Territories**</b>						
French Guiana	6	0	0	0	Imported cases only	1
Martinique	6	2	0	0	Imported cases only	0
Saint Martin	2	0	0	0	Under investigation	11
Saint Barthelemy	1	0	0	0	Under investigation	11
Cayman Islands	1	1	0	0	Imported cases only	0
<b>African Region</b>						
Algeria	26	1	2	1	Local transmission	0
South Africa	17	0	0	0	Local transmission	1
Senegal	10	0	0	0	Local transmission	1
Burkina Faso	2	0	0	0	Imported cases only	3
Cameroon	2	0	0	0	Local transmission	7
Democratic Republic of the Congo	2	1	0	0	Imported cases only	0
Nigeria	2	0	0	0	Imported cases only	5
Cote d'Ivoire	1	0	0	0	Imported cases only	2
Ethiopia	1	1	0	0	Imported cases only	0
Gabon	1	1	0	0	Imported cases only	0
Ghana	1	1	0	0	Imported cases only	0
Guinea	1	1	0	0	Imported cases only	0
Kenya	1	1	0	0	Imported cases only	0
Togo	1	0	0	0	Imported cases only	7
<b>Territories**</b>						
Réunion	5	2	0	0	Imported cases only	0
<b>Subtotal for all regions</b>	<b>60821</b>	<b>9750</b>	<b>2192</b>	<b>424</b>		
International conveyance	697	1	7	0	Local transmission	0

(Diamond Princess)						
<b>Grand total</b>	<b>61518</b>	<b>9751</b>	<b>2199</b>	<b>424</b>		

\*Numbers include both domestic and repatriated cases

†The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

‡Case classifications are based on [WHO case definitions](#) for COVID-19.


§Transmission classification is based on WHO analysis of available official data and may be subject to reclassification as additional data become available. Countries/territories/areas experiencing multiple types of transmission are classified in the highest category for which there is evidence; they may be removed from a given category if interruption of transmission can be demonstrated. It should be noted that even within categories, different countries/territories/areas may have differing degrees of transmission as indicated by the differing numbers of cases and other factors. Not all locations within a given country/territory/area are equally affected.

Terms:

- **Community transmission** is evidenced by the inability to relate confirmed cases through chains of transmission for a large number of cases, or by increasing positive tests through sentinel samples (routine systematic testing of respiratory samples from established laboratories).
- **Local transmission** indicates locations where the source of infection is within the reporting location.
- **Imported cases only** indicates locations where all cases have been acquired outside the location of reporting.
- **Under investigation** indicates locations where type of transmission has not been determined for any cases.
- **Interrupted transmission** indicates locations where interruption of transmission has been demonstrated (details to be determined)

\*\* "Territories" include territories, areas, overseas dependencies and other jurisdictions of similar status

**Figure 2. Epidemic curve of confirmed COVID-19 cases reported outside of China (n=61 518), by date of report and WHO region through 14 March 2020**



## STRATEGIC OBJECTIVES

WHO's strategic objectives for this response are to:

- Interrupt human-to-human transmission including reducing secondary infections among close contacts and health care workers, preventing transmission amplification events, and preventing further international spread\*;
- Identify, isolate and care for patients early, including providing optimized care for infected patients;
- Identify and reduce transmission from the animal source;
- Address crucial unknowns regarding clinical severity, extent of transmission and infection, treatment options, and accelerate the development of diagnostics, therapeutics and vaccines;
- Communicate critical risk and event information to all communities and counter misinformation;
- Minimize social and economic impact through multisectoral partnerships.

\*This can be achieved through a combination of public health measures, such as rapid identification, diagnosis and management of the cases, identification and follow up of the contacts, infection prevention and control in health care settings, implementation of health measures for travelers, awareness-raising in the population and risk communication.

## PREPAREDNESS AND RESPONSE

- To view all technical guidance documents regarding COVID-19, please go to [this webpage](#).
- WHO has developed interim guidance for laboratory diagnosis, advice on the use of masks during home care and in health care settings in the context of the novel coronavirus (2019-nCoV) outbreak, clinical management, infection prevention and control in health care settings, home care for patients with suspected novel coronavirus, risk communication and community engagement and Global Surveillance for human infection with novel coronavirus (2019-nCoV).
- WHO is working closely with International Air Transport Association (IATA) and have jointly developed a guidance document to provide advice to cabin crew and airport workers, based on country queries. The guidance can be found on the [IATA webpage](#).
- WHO has been in regular and direct contact with Member States where cases have been reported. WHO is also informing other countries about the situation and providing support as requested.
- WHO is working with its networks of researchers and other experts to coordinate global work on surveillance, epidemiology, mathematical modelling, diagnostics and virology, clinical care and treatment, infection prevention and control, and risk communication. WHO has issued interim guidance for countries, which are updated regularly.
- WHO has prepared a [disease commodity package](#) that includes an essential list of biomedical equipment, medicines and supplies necessary to care for patients with 2019-nCoV.
- WHO has provided recommendations to reduce risk of [transmission from animals to humans](#).
- WHO has published an [updated advice for international traffic in relation to the outbreak of the novel coronavirus 2019-nCoV](#).
- WHO has activated the R&D blueprint to accelerate diagnostics, vaccines, and therapeutics.
- OpenWHO is an interactive, web-based, knowledge-transfer platform offering online courses to improve the response to health emergencies. [COVID-19 courses can be found here](#). Specifically, WHO has developed online courses on the following topics: A general introduction to emerging respiratory viruses, including novel coronaviruses (available in Arabic, English, French, Chinese, Spanish, Portuguese, and Russian); Critical Care of Severe Acute Respiratory Infections (available in English and French); Health and safety briefing for respiratory diseases - ePROTECT (available in English, French, and Russian); Infection Prevention and Control for Novel

Coronavirus (COVID-19) (available in English and Russian); and COVID-19 Operational Planning Guidelines and COVID-19 Partners Platform to support country preparedness and response.

- WHO is providing guidance on early investigations, which are critical in an outbreak of a new virus. The data collected from the protocols can be used to refine recommendations for surveillance and case definitions, to characterize the key epidemiological transmission features of COVID-19, help understand spread, severity, spectrum of disease, impact on the community and to inform operational models for implementation of countermeasures such as case isolation, contact tracing and isolation. Several protocols are available [here](#). One such protocol is for the investigation of early COVID-19 cases and contacts (the “[First Few X \(FFX\) Cases and contact investigation protocol for 2019-novel coronavirus \(2019-nCoV\) infection](#)”). The protocol is designed to gain an early understanding of the key clinical, epidemiological and virological characteristics of the first cases of COVID-19 infection detected in any individual country, to inform the development and updating of public health guidance to manage cases and reduce the potential spread and impact of infection.

## RECOMMENDATIONS AND ADVICE FOR THE PUBLIC

If you are not in an area where COVID-19 is spreading or have not travelled from an area where COVID-19 is spreading or have not been in contact with an infected patient, your risk of infection is low. It is understandable that you may feel anxious about the outbreak. Get the facts from reliable sources to help you accurately determine your risks so that you can take reasonable precautions (see [Frequently Asked Questions](#)). Seek guidance from WHO, your healthcare provider, your national public health authority or your employer for accurate information on COVID-19 and whether COVID-19 is circulating where you live. It is important to be informed of the situation and take appropriate measures to protect yourself and your family (see [Protection measures for everyone](#)).

If you are in an area where there are cases of COVID-19 you need to take the risk of infection seriously. Follow the advice of WHO and guidance issued by national and local health authorities. For most people, COVID-19 infection will cause mild illness however, it can make some people very ill and, in some people, it can be fatal. Older people, and those with pre-existing medical conditions (such as cardiovascular disease, chronic respiratory disease or diabetes) are at risk for severe disease (See [Protection measures for persons who are in or have recently visited \(past 14 days\) areas where COVID-19 is spreading](#)).

## CASE DEFINITIONS

WHO periodically updates the [Global Surveillance for human infection with coronavirus disease \(COVID-19\)](#) document which includes case definitions.

For easy reference, case definitions are included below.

### **Suspect case**

A. A patient with acute respiratory illness (fever and at least one sign/symptom of respiratory disease (e.g., cough, shortness of breath), AND with no other etiology that fully explains the clinical presentation AND a history of travel to or residence in a country/area or territory reporting local transmission (See [situation report](#)) of COVID-19 disease during the 14 days prior to symptom onset.

**OR**

B. A patient with any acute respiratory illness AND having been in contact with a confirmed or probable COVID-19 case (see definition of contact) in the last 14 days prior to onset of symptoms;

**OR**

C. A patient with severe acute respiratory infection (fever and at least one sign/symptom of respiratory disease (e.g., cough, shortness breath) AND requiring hospitalization AND with no other etiology that fully explains



the clinical presentation.

**Probable case**

A suspect case for whom testing for COVID-19 is inconclusive.

- Inconclusive being the result of the test reported by the laboratory

**Confirmed case**

A person with laboratory confirmation of COVID-19 infection, irrespective of clinical signs and symptoms.

- Information regarding laboratory guidance can be found [here](#).